FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease

Oncogene

Volumn 18, Issue 17, 1999, Pages 2755-2761

  Dorkin, Trevor J ^a   Robinson, Mary C ^b   Marsh, Colin ^b   Bjartell, Anders ^c   Neal, David E ^a   Leung, Hing Y ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Androgen independent; FGF8; Patient survival; Prostate cancer

Indexed keywords

FIBROBLAST GROWTH FACTOR; MESSENGER RNA;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL FUNCTION; CONTROLLED STUDY; GERM LAYER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY;

ADULT; ANDROGENS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 0033614366     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1202624     Document Type: Article

References (21)

1. Crossley PH, Minowuda G, MacArthur CA and Martin GR. (1996). Cell, 84, 127-136.
2. Gemel J, Gorry M, Erhlich GD and MacArthur CA. (1996). Genontics, 35, 253-257.
3. Ghosh AK, Shankar DB, Shackleford GM, Wu K, T'Ang A, Miller GJ, Zheng J and Roy-Burman P. (1996). Cell, Growth & Differ., 7, 1425-1435.
4. Ittman M and Mansukhani A. (1997). J. Urol., 157, 351-356.
5. Lee SM, Danielian PS, Fritzsch B and McMahon AP. (1997). Development. 124, 959-969.
6. Leung HY, Dickson C, Robson CN and Neal DE. (1996). Oncogene, 12, 1833-1835.
7. Leung HY, Mehta P, Gray L, Collins AT, Robson CN and Neal DE. (1997). Oncogene, 15, 1115-1120.
8. MacArthur CA, Lawshe A, Xu J, Santos-Ocamp S, Heikinheimo M, Chellaiah AT and Ornitz DM. (1995a). Development, 121, 3603-3613.
9. MacArthur CA, Lawshe A, Shankar DB, Heikinheimo M and Shackleford GM. (1995b). Cell Growth & Differ., 6, 817-825.
10. Mason I. (1994). Cell, 78, 547-552.
11. Myers RL, Chedid M, Tronick SR and Chiu I-M. (1995). Oncogene, 11, 785-789.
12. Office For National Statistics. (1996). Population and Health Monitor DH2 96/2.
13. Payson RA, Wu J, Liu Y and Chiu I-M. (1996). Oncogene, 13, 47-53.
14. Rudra-Ganguly N, Zheng J, Hoang AT and Roy-Burman P. (1998). Oncogene, 16, 1487-1492.
15. Schmitt JF, Hearn MT and Risbridger GP. (1996). J. Steroid Bioehem. Mol. Biol., 57, 173-178.
16. Smallwood PM, Munoz-Sanguan I, Tong P, Macke JP, Hendry SHC, Gilbert DJ, Copeland NG, Jenkins NA and Nathans J. (1996). Proc. Natl. Acad. Sci. USA, 93, 9850-9857.
17. Susuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB and Bova GS. (1998). Cancer Res., 58, 204-209.
18. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H and Matsumoto K. (1992). Proc. Natl. Acad. Sci. USA, 89, 8928-8932.
19. Tanaka A, Miyamoto K, Matsuo H, Matsumoto K, Yoshida H. (1995). FEBS Lett., 363, 226-230.
20. Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H, Koike M and Fukayama M. (1998). Cancer Res., 58, 2053-2056.
21. Yazidi IE, and Boilly-Marer Y. (1995). Anticancer Res., 15, 783-790.